Results 181 to 190 of about 68,056 (282)

Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. [PDF]

open access: yesNeuro Oncol
Gupta P   +29 more
europepmc   +1 more source

Bovine Endometrium Drives and Responds to Divergence of In Vitro Produced Conceptus Biochemistry

open access: yesThe FASEB Journal, Volume 39, Issue 16, 31 August 2025.
IVD versus IVP bovine conceptus‐endometrial microenvironment. Compared to the in vivo derived (IVD) bovine conceptus, the in vitro produced (IVP) conceptus has a reduced number of transcribed genes, mRNA abundance for genes transcribed and increased expression of inflammatory mediators in response to the endometrium.
Katheryn D. Peterson   +14 more
wiley   +1 more source

Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas. [PDF]

open access: yesAnn Clin Transl Neurol
Zhao D   +12 more
europepmc   +1 more source

Locations of the Regulatory Sites for Isocitrate Dehydrogenase Kinase/Phosphatase [PDF]

open access: hybrid, 2000
Stephen P. Miller   +5 more
openalex   +1 more source

Identification of a l‐Threonine‐Utilizing Hydrazine Synthetase for Thrazarine Biosynthesis in Streptomyces coerulescens MH802‐fF5

open access: yesChemBioChem, Volume 26, Issue 15, August 22, 2025.
A putative thrazarine biosynthetic gene cluster is discovered in the genome sequence of Streptomyces coerulescens MH802‐fF5. In vivo and in vitro analyses of ThzN, a hydrazine synthetase with cupin and methionyl‐tRNA synthetase‐like domains encoded in the cluster, showed that it synthesizes a key intermediate of thrazarine by catalyzing condensation ...
Yusuke Shikai   +4 more
wiley   +1 more source

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort

open access: yesCancer, Volume 131, Issue 16, 15 August 2025.
Abstract Background Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase 2, multicohort LEAP‐005 study (NCT03797326).
Sun Young Rha   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy